This research presents a luminescent calcium biosensor that enables endpoint measurement of GPCR activation, streamlining drug discovery and biomarker quantification.
Gq/11-coupled GPCRs regulate critical physiological processes through calcium mobilization, making intracellular Ca²⁺ dynamics a key readout for drug discovery and biomarker detection. However, the transient nature of calcium signals necessitates real-time monitoring with specialized equipment, creating barriers for high-throughput screening and limiting accessibility. Here we present CalLuc-2.1, a luminescent calcium biosensor that converts brief Ca²⁺ spikes into persistent luminescence changes readable tens of minutes after stimulation. By eliminating the need for precisely-timed detection, CalLuc-2.1 enables endpoint measurement of GPCR activation using standard plate readers. We demonstrate robust performance (Z' > 0.88) across multiple Gq/11-coupled GPCRs in both agonist and antagonist screening formats. Furthermore, CalLuc-2.1 successfully detects endogenous GPCR ligands directly in human serum, offering a simpler alternative to immunoassays and mass spectrometry for biomarker quantification. This approach makes calcium-based GPCR assays accessible to any laboratory with basic luminescence detection capabilities, potentially accelerating both drug discovery and clinical research applications.
No takes yet. Share an insight, caveat, or question.
Doi et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: